Loading...

PDSB PDS BIOTECHNOLOGY CORP Product Launches 8-K Filing

PDS

PDSB

PDS BIOTECHNOLOGY CORP

(PDSB)

2025 8-K

Financial Results Update

Delisting Warning

Corporate Update

Protocol Amendment

Study Results Announced

Patent Approval

Protocol Amendment

Patent Approval

FDA Meeting Scheduled

Financial Update

Securities Agreement

Positive Clinical Data

FDA Meeting Request

Clinical Trial Update

Corporate Update

Clinical Trial Data

Financial Update

Market Expansion

Compensatory Arrangements o...

Research Announcement

Clinical Trials

Financial Statements

New Product Launches

Debt-Equity Swaps

Securities Offering

Clinical Trial Update

Public Offering

Public Offering

Clinical Trial Update

Earnings Reports

Quantitative Data

Annual Meeting and Amendmen...

Filing Letter with Quantita...

Merger of Equals

Earnings Reports

Quantitative Data

Merger of Equals

Quantitative Data

Quantitative Data Mentioned

Filing Letter with Quantita...

Quantitative Data Mentioned

Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data

Annual Meeting Approval

Quantitative Data

Quantitative Data Mentioned

Quantitative Data

Quantitative Data Mentioned

Quantitative Data Mentioned

Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data Mentioned

Quantitative Data

External Links:

On August 25, 2025, PDS Biotechnology Corp announced final survival data from its VERSATILE-002 Phase 2 clinical trial evaluating PDS0101 (Versamune® HPV) combined with Keytruda® in treating head and neck cancer patients.

AI Assistant

PDS BIOTECHNOLOGY CORP

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.